S. J. O. Veldhuyzen Van Zanten
University of Alberta
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by S. J. O. Veldhuyzen Van Zanten.
Alimentary Pharmacology & Therapeutics | 2003
Abr Thomson; Alan N. Barkun; David Armstrong; Naoki Chiba; R. J. White; Sandra Daniels; Sergio Escobedo; Bijan Chakraborty; Paul Sinclair; S. J. O. Veldhuyzen Van Zanten
Background: Uninvestigated dyspepsia is common in family practice. The prevalence of clinically significant upper gastrointestinal findings (CSFs) in adult uninvestigated dyspepsia patients, and their predictability based on history, is unknown.
Journal of Clinical Epidemiology | 1993
S. J. O. Veldhuyzen Van Zanten; K. M. A. J. Tytgat; P.T. Pollak; J. Goldie; R.L. Goodacre; R.H. Riddell; R. H. Hunt
Most trials of non-ulcer dyspepsia (NUD) and Helicobacter pylori associated gastritis (HPAG) have not used validated methods of measuring symptoms. Three attributes are necessary for use of symptom severity scoring systems as outcome measures in clinical trials: reproducibility, responsiveness to change and validity compared to corroborating measures. The objective of this study was to establish that selected gastrointestinal symptoms recorded as a series of 5-point Likert Scales meet the 3 criteria for use as outcome measures in clinical trials. Patients with NUD (Helicobacter pylori-negative) and HPAG were studied. A preliminary assessment of 24 patients was used to select the 8 most frequently occurring and most severe symptoms. These symptoms were then scored in a further 55 patients to assess their utility as outcome measures. Observations were made at 3 time points, enrollment (T1), after 1 week with no intervention (T2) and after 4 weeks of therapy for either disease (T3). The study took place in a university hospital outpatient gastroenterology service. Symptom scores were reproducible before treatment (symptom scores at T1 and T2 were correlated), responsive (symptom scores changed after treatment between T2 and T3) and valid (symptom score changes corresponded to changes in general health status). Scoring of gastrointestinal symptom severity using 5-point Likert Scales satisfies the 3 criteria for use as outcome measures in clinical trials of NUD and HPAG.
Alimentary Pharmacology & Therapeutics | 2012
Bing Guo; Christa Harstall; T. Louie; S. J. O. Veldhuyzen Van Zanten; Levinus A. Dieleman
Management of recurrent Clostridium difficile‐associated disease (CDAD), particularly in elderly patients, remains clinically challenging. Faecal transplantation (FT) may restore normal microbiota and break the cycle of recurrent CDAD.
Gut | 2008
Alexander C. Ford; S. J. O. Veldhuyzen Van Zanten; C C Rodgers; Nicholas J. Talley; Nimish Vakil; P Moayyedi
Objective: Colorectal cancer is the second most common cause of cancer death in Europe and North America. Alarm features are used to prioritise access to urgent investigation, but there is little information concerning their utility in the diagnosis of colorectal cancer. Methods: A systematic review and meta-analysis of the published literature was carried out to assess the diagnostic accuracy of alarm features in predicting colorectal cancer. Primary or secondary care-based studies in unselected cohorts of adult patients with lower gastrointestinal symptoms were identified by searching MEDLINE, EMBASE and CINAHL (up to October 2007). The main outcome measures were accuracy of alarm features or statistical models in predicting the presence of colorectal cancer after investigation. Data were pooled to estimate sensitivity, specificity, and positive and negative likelihood ratios. The quality of the included studies was assessed according to predefined criteria. Results: Of 11 169 studies identified, 205 were retrieved for evaluation. Fifteen studies were eligible for inclusion, evaluating 19 443 patients, with a pooled prevalence of colorectal carcinoma of 6% (95% CI 5% to 8%). Pooled sensitivity of alarm features was poor (5% to 64%) but specificity was >95% for dark red rectal bleeding and abdominal mass, suggesting that the presence of either rules the diagnosis of colorectal cancer in. Statistical models had a sensitivity of 90%, but poor specificity. Conclusions: Most alarm features had poor sensitivity and specificity for the diagnosis of colorectal carcinoma, whilst statistical models performed better in terms of sensitivity. Future studies should examine the utility of dark red rectal bleeding and abdominal mass, and concentrate on maximising specificity when validating statistical models.
Alimentary Pharmacology & Therapeutics | 2001
H. A. Redstone; N. Barrowman; S. J. O. Veldhuyzen Van Zanten
To perform a meta‐analysis evaluating the efficacy of H2‐receptor antagonists in functional (nonulcer) dyspepsia.
Alimentary Pharmacology & Therapeutics | 2004
N. S. Abraham; Paul Moayyedi; Bryan A. Daniels; S. J. O. Veldhuyzen Van Zanten
Aim : To evaluate treatment efficacy using objective quality criteria.
Alimentary Pharmacology & Therapeutics | 2006
S. J. O. Veldhuyzen Van Zanten; Naoki Chiba; David Armstrong; Alan N. Barkun; Abr Thomson; V. Mann; Sergio Escobedo; Bijan Chakraborty; K. Nevin
Background Currently there is no consensus on the optimal method to measure the severity of dyspepsia symptoms in clinical trials.
Alimentary Pharmacology & Therapeutics | 2007
Hiroto Miwa; K. Nakajima; Kanako Yamaguchi; Kazuma Fujimoto; S. J. O. Veldhuyzen Van Zanten; Yoshikazu Kinoshita; Kyoichi Adachi; Hiroaki Kusunoki; Ken Haruma
Objective The relationship between acid and dyspeptic symptoms has not been fully understood.
Alimentary Pharmacology & Therapeutics | 2005
David Armstrong; S. J. O. Veldhuyzen Van Zanten; Alan N. Barkun; Naoki Chiba; Abr Thomson; Sandra Smyth; Paul Sinclair; Bijan Chakraborty; R. J. White
Background : There are few data on empiric, stepped therapy for heartburn relief or subsequent relapse in primary care.
Alimentary Pharmacology & Therapeutics | 2004
Naoki Chiba; S. J. O. Veldhuyzen Van Zanten; Sergio Escobedo; E. Grace; J. Lee; Paul Sinclair; Alan N. Barkun; David Armstrong; Abr Thomson
Background : Adult Helicobacter pylori‐positive patients by 13C‐urea breath test with uninvestigated dyspepsia symptoms were randomized to 1‐week eradication treatment with omeprazole, metronidazole and clarithromycin (OMC) vs. omeprazole and placebo antimicrobials (OPP) in the Canadian Adult Dyspepsia Empiric Treatment—H. pylori‐positive (CADET‐Hp) study.